Loading...
The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis
Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...
Na minha lista:
| Udgivet i: | Cell Death Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5849039/ https://ncbi.nlm.nih.gov/pubmed/29317636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0026-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|